ERCC3 and adenocarcinoma: Interestingly, CP341 (RB1 alteration, ATM/ERCC3/TP53 mutant, adenocarcinoma) PDX-Os were more sensitive to DS-7300a than CP50C (ATM loss, adenocarcinoma) despite having lower target expression.